Peptide comparison
Both mimic GHRH to stimulate growth hormone release from the pituitary. Tesamorelin keeps the full hormone and protects its starting end; CJC-1295 uses a shorter fragment with substitutions and, in its DAC version, binds to albumin. The result is very different action profiles and clinical paths.
Compare mechanism, class, receptors and evidence. All compounds are offered with ≥99% purity verified by HPLC and a batch COA.
| Tesamorelin | CJC-1295 (with DAC) | |
|---|---|---|
| Base | Full GHRH (44 amino acids) | GHRH(1-29) fragment |
| Protection against enzymes | Trans-3-hexenoyl group at the N-terminus | Four amino acid substitutions |
| Half-life extension | No: short-acting | Yes: covalent albumin binding (DAC) |
| Exposure pattern | Brief peaks | Sustained over days |
| Clinical development | Completed for a specific indication | Early-phase studies, not taken through to approval |
| Status | FDA-approved medicine for a specific indication | Not approved as a medicine |
Tesamorelin solves the breakdown problem with a minimal change: it keeps the 44 amino acids of natural GHRH and adds a chemical group at the N-terminus that prevents cleavage by DPP-4. Its action remains short and pulsatile. It is the GHRH analogue with the most complete clinical development, which culminated in its approval to reduce excess abdominal fat in a specific patient population.
CJC-1295 follows a different logic: it starts from the shorter active fragment, reinforces it with substitutions and, in the DAC version, anchors it to albumin to turn a brief signal into days of exposure. It was studied in early clinical phases but was never approved. Comparing the two means comparing an “almost natural hormone” strategy with a “long-acting” one.
💡 Want the complete scientific foundations? See the Peptide guide or the Certification in Peptide Science.
Yes. Both are GHRH analogues and activate the GHRH receptor in the pituitary. They differ in structure, half-life and the type of signal they produce.
Tesamorelin, which completed its clinical development and is approved as a medicine for a specific indication. CJC-1295 only has early-phase clinical studies.
Because its design aims to keep a short-acting profile close to natural GHRH. DAC albumin binding pursues exactly the opposite: sustained exposure.
Purity ≥99% verificada por HPLC and batch COA.
View full catalog →